Skip over navigation
Banner
Directory
Directory Search
Jobs
Job Search Post a Job
Patient
Patient Resources Drug Development
History
Genealogy
Toons & Teasers
Industry
 Directory
 Toons & Teasers
Quick Links
 Directory
 Job Search
 Toons & Teasers
 Advertising
 
Events
 

EquipNet Auction: Sell Your Surplus Equipment on Our Global Marketplace Now!

Our Newest Cartoon Illustrates: "The Biology of Valentines"


Washington Life Science Industry Directory

https://www.cdc.gov/flu/prevent/index.html

Banner Advertising

Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and delayed by COVID-19, to be launched in 2023 replacing WashingtonLifeScience.com. Regrettably, we are working with reduced staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved directory upon the launch of the new site. We apologize for the inconvenience.

Nativis Inc.


Nativis Inc.
24 Roy Street, Suite 437
Seattle, WA 98109
Nativis Inc.
 
Phone: (206) 708-2288
Year Established:  2002
Main Contact: Michael Mischke-ReedsMischke-Reeds, Senior VP, Business Development
 
Other Contacts:  Michael K. Matysik, MBA, CFO
Donna Morgan Murray, PhD, CRO
Deborah Sheffield, MSc, Head of Quality Systems, Clinical and Regulatory Affairs
Xavier A. Figueroa, Ph.D., Director, Pre-clinical Development
Steven E. Pope, Senior VP, General Counsel
Kenneth Ferguson, Ph.D., CSO
Eric Peterson, Director of Development & Manufacturing
Chris E. Rivera, President & CEO
 
Company Description
Nativis, formerly WavBank, is a clinical-stage bio-electronics company. Nativis has invented and patented a groundbreaking technology that utilizes precisely targeted, ultra-low radio frequency energy (ulRFE) to specifically regulate metabolic pathways on the molecular and genetic levels – without chemicals, radiation or drugs – delivered via a simple-to-use non-invasive device called Nativis Voyager®. The company’s goal is to transform disease treatment on a global scale with ulRFE that can potentially be applied to a wide range of conditions and other health-related needs (including agriculture, bio-fuels and veterinary medicine, to name a few). Nativis’ initial focus is on the treatment of patients with brain cancer (initially, recurrent glioblastoma), who are not well served by conventional standard of care therapies, which often result in poor outcomes and devastating side effects. Additional pre-clinical work is being completed for melanoma, lung cancer, liver cancer, inflammatory disease and chronic pain.


Main Industry Directory

 
Email thie page to a friend. Email This Page
to a Friend
Print this page. Print This
Page
© 1997 - 2023 Info.Resource, Inc. All rights reserved.
Privacy Policy . Cookie Policy . Terms of Use . About . Advertising

WashingtonLifeScience.com is owned and published by Info.Resource, Inc.